FRAMINGHAM, MA--(Marketwire - March 26, 2008) - The GI Company, Inc., a privately held developer of gastrointestinal therapeutics, today announced that an abstract detailing results from a Phase II clinical trial (2006 - ITF - 009) has been accepted for oral presentation at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). This Phase II study is titled, Prophylaxis of recurrent chemotherapy-induced oral mucositis: A Phase II multicenter, randomized, placebo-controlled trial of recombinant human intestinal trefoil factor (rhITF).
